NZ Multiple Myeloma Research Review Issue 44

In this issue:
  -  Second ISS revision for OS in MM
  -  CTCs for staging newly diagnosed transplant-eligible MM
  -  Impact of autologous HCT on disease burden by NGS in quadruplet-treated MM
  -  Paraskeletal and EMPs at MM diagnosis and first relapse
  -  Neutralising antibody response after SARS-COV-2 vaccination in myeloma
  -  Teclistamab for relapsed/ refractory MM
  -  Cost effectiveness of frontline daratumumab in transplant-eligible newly diagnosed MM
  -  Early mortality predictors in MM
  -  Isatuximab ±Kd in relapsed MM with high-risk cytogenetics
  -  VTE risk with adding daratumumab to RVd in newly diagnosed MM

Please login below to download this issue (PDF)

Subscribe